Cline Scientific decides to postpone rights issue

Cline Scientific AB (publ) ("Cline" or the "Company") has, following Friday's news regarding the company's CEO, decided to postpone the rights issue whose subscription period was to begin today, May 8.

Due to the uncertainties surrounding the company's CEO, who has been notified of suspicion of market manipulation, the Company's board, on the advice of advisors, has decided to postpone the announced rights issue. The company will return with further information when the issue will be carried out.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.

 This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 8:56 CEST on 8 May 2023.

For more information, please contact:

Johan Bjurquist, Chairman of the board
Phone: 073-747 1990

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.